76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

J.O Park,D.T Wai Meng,A Hollebecque,M Borad,L Goyal,A Schram,P Cassier,S.D Kamath,E Dotan,R Kim,V Sahai,C-Y Liao,M Millward,D Roda Perez,R Blakesley,B Wolf,V Subbiah,R.K Kelley,D-Y Oh

doi:10.1016/j.annonc.2022.10.112

76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

J.O Park, D.T Wai Meng + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.112

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
Citations: 5	License type: publisher-specific-oa

Affiliation: Samsung Medical Center, Sungkyunkwan University, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, He University, University of Chicago, University of Western Australia, Hospital Clínico Universitario de Valencia, The University of Texas MD Anderson Cancer Center, Seoul National University Hospital

#Target In CCA #FGFR2 Inhibitor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Previous, nonselective FGFRi have validated FGFR2 f/r as a target in CCA by achieving an objective response rate (ORR) of ∼20-40% with duration of response (DOR) ∼5-9 months. However, off-target toxicity and emergence of polyclonal FGFR2 resistance limit their efficacy. RLY-4008 is the first highly selective, potent FGFR2 inhibitor designed to target both driver alterations and FGFR resistance mutations. Here we present the initial efficacy of RLY-4008 in pts with a FGFR2 f/r, FGFRi-naïve CCA.

Full Text